Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients

The introduction of protease inhibitors (PI) containing antiretroviral regimens in the treatment of HIV infection in infants, children, and adolescents has dramatically decreased morbidity and mortality. Darunavir, the latest PI to be FDA approved for pediatric patients older than 6 years and curren...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobroszycki, Joanna, Abadi, Jacobo, Wiznia, Andrew A, Rosenberg, Michael G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926773/
https://www.ncbi.nlm.nih.gov/pubmed/24600277
http://dx.doi.org/10.2147/AHMT.S11177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926773/
https://www.ncbi.nlm.nih.gov/pubmed/24600277
http://dx.doi.org/10.2147/AHMT.S11177

Ejemplares similares